Home » Health » Study examines link to vaccination

Study examines link to vaccination

Toulouse researchers have studied the risk of declaring inflammation of the heart muscle after Covid-19 vaccination in 12-17 year olds.

A Toulouse research team has just published a study investigating the risks of declaring myocarditis and / or pericarditis in adolescents aged 12 to 17 years who have received one or two doses of messenger RNA vaccine (Pfizer and Moderna) . Myocarditis is inflammation of the heart muscle; pericarditis an inflammation of the fibrous sac surrounding the heart. The work was carried out by members of the medical pharmacology and cardiology (adult and pediatric) departments of the Toulouse University Hospital Center (CHU).

“We analyzed all the reports of adverse reactions from data from the global pharmacovigilance database and mainly from European countries, until September 14, 2021”, explains Dr François Montastruc, pharmacologist at the pharmacovigilance center of the CHU de Toulouse, principal investigator of the study, who worked within the framework of the project of the National Agency of Research ANR Vigi-Drugs.

A poorly understood pathology

“Among the 4,942 reports analyzed in adolescents, we identified 242 reports of myocarditis or pericarditis. In eight cases out of ten, hospitalization was necessary. The average time to onset of the first symptoms was 4 days after the first dose and 3 days after the second. Our results suggest that the risk of declaring is five times greater at the second dose than for the first. We also find that the risk of declaring myocarditis or pericarditis is ten times greater in boys than for the first. either at the first or at the second dose “, adds Dr Montastruc.

“Myocarditis is a cardiac pathology which is not rare and which affects more young subjects between 15 and 30 years old and more particularly men. It is still rather poorly understood. The Covid-19 virus has revived the debates on the occurrence of myocarditis (10% of myocarditis recorded since March 2020 would be potentially associated with Covid-19) and rare cases of post-vaccine myocarditis have also caused a lot of talk “, explains Dr Clément Delmas, cardiologist at the Toulouse University Hospital, co -author of the study.

Space out the doses

“French data from pharmacovigilance centers showed an increase in the number of declarations of myocarditis between the months of May and September 2021, which corresponds to the period of acceleration of the vaccination campaign and its extension to young people” , further specifies the doctor.

He concludes: “This study brings additional elements to the discussions around the vaccine regimens used in particular in young male adolescents. Thus some countries have recommended the realization of a single dose in this population like England, others a spacing of the doses. doses. Research must continue. In any case, our results do not call into question the interest and the benefit / risk ratio of vaccination even in these populations. “

Study examines link to vaccination

A Toulouse research team has just published a study investigating the risks of declaring myocarditis and / or pericarditis in adolescents aged 12 to 17 years who have received one or two doses of messenger RNA vaccine (Pfizer and Moderna) . Myocarditis is inflammation of the heart muscle; pericarditis an inflammation of the fibrous sac surrounding the heart. The work was carried out by members of the medical pharmacology and cardiology (adult and pediatric) departments of the Toulouse University Hospital Center (CHU).

“We analyzed all the reports of adverse reactions from data from the global pharmacovigilance database and mainly from European countries, until September 14, 2021”, explains Dr François Montastruc, pharmacologist at the pharmacovigilance center of the CHU de Toulouse, principal investigator of the study, who worked within the framework of the project of the National Agency of Research ANR Vigi-Drugs.

A poorly understood pathology

“Among the 4,942 reports analyzed in adolescents, we identified 242 reports of myocarditis or pericarditis. In eight cases out of ten, hospitalization was necessary. The average time to onset of the first symptoms was 4 days after the first dose and 3 days after the second. Our results suggest that the risk of declaring is five times greater at the second dose than for the first. We also find that the risk of declaring myocarditis or pericarditis is ten times greater in boys than for the first. either at the first or at the second dose “, adds Dr Montastruc.

“Myocarditis is a cardiac pathology which is not rare and which affects more young subjects between 15 and 30 years old and more particularly men. It is still rather poorly understood. The Covid-19 virus has revived the debates on the occurrence of myocarditis (10% of myocarditis recorded since March 2020 would be potentially associated with Covid-19) and rare cases of post-vaccine myocarditis have also caused a lot of talk “, explains Dr Clément Delmas, cardiologist at the Toulouse University Hospital, co -author of the study.

Space out the doses

“French data from pharmacovigilance centers showed an increase in the number of declarations of myocarditis between the months of May and September 2021, which corresponds to the period of acceleration of the vaccination campaign and its extension to young people” , further specifies the doctor.

He concludes: “This study brings additional elements to the discussions around the vaccine regimens used in particular in young male adolescents. Thus some countries have recommended the realization of a single dose in this population like England, others a spacing of the doses. doses. Research must continue. In any case, our results do not call into question the interest and the benefit / risk ratio of vaccination even in these populations. “

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.